Acumen's Late-2026 Sabirnetug Readout Is A Viable Bet
Acumen Pharmaceuticals, Inc. (ABOS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Acumen Pharmaceuticals, Inc. (ABOS) Q1 2026 Earnings Call Transcript
Acumen Pharmaceuticals Q1 Earnings Call Highlights
Acumen Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Highlights
Acumen Pharmaceuticals to Participate in the Bank of America Securities 2026 Health Care Conference
Acumen Pharmaceuticals to Report First Quarter Financial Results on May 12, 2026
Acumen Pharmaceuticals (ABOS) Loses 33.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Is Acumen Pharmaceuticals (ABOS) Stock Outpacing Its Medical Peers This Year?
Analysts Set Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Target Price at $7.00
Acumen Pharmaceuticals, Inc. (ABOS) Q4 2025 Earnings Call Transcript
Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2025 and Business Highlights
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2025 Financial Results on March 26, 2026
Acumen Pharmaceuticals Announces $35.75 Million Private Placement to Advance Potential Best-in-Class Molecules from Amyloid Beta Oligomer-Selective Enhanced Brain Delivery Portfolio
Acumen Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum
Daniel Joseph Oconnell Sells 12,941 Shares of Acumen Pharmaceuticals (NASDAQ:ABOS) Stock
Matt Zuga Sells 6,888 Shares of Acumen Pharmaceuticals (NASDAQ:ABOS) Stock
Daniel Joseph Oconnell Sells 8,143 Shares of Acumen Pharmaceuticals (NASDAQ:ABOS) Stock
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Receives Average Rating of “Moderate Buy” from Brokerages
Financial Review: Acumen Pharmaceuticals (NASDAQ:ABOS) versus Bolt Biotherapeutics (NASDAQ:BOLT)
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Receives $6.75 Average Target Price from Analysts
Acumen Pharmaceuticals, Inc. (ABOS) Q3 2025 Earnings Call Transcript
Acumen Pharmaceuticals, Inc. (ABOS) Presents At Citi's Biopharma Back To School Conference Transcript
Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences
Acumen Pharmaceuticals, Inc. (ABOS) Q2 2025 Earnings Call Transcript
Acumen Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Highlights
Acumen Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 12, 2025
JCR Pharmaceuticals and Acumen Pharmaceuticals Announce Collaboration to Develop Therapy for Alzheimer's Disease, Enabled by J-Brain Cargo® Technology Platform
Acumen Pharmaceuticals to Present Studies on Cost Savings Associated with Use of pTau217 Screening Assay in Phase 2 ALTITUDE-AD Study and Sabirnetug Oligomer-Selectivity at the Alzheimer's Association International Conference (AAIC®) 2025
Acumen Pharmaceuticals, Inc. (ABOS) Q1 2025 Earnings Call Transcript
Acumen Pharmaceuticals to Participate in the Bank of America Healthcare Conference
Acumen Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025
Acumen Pharmaceuticals Showcases pTau217 Trial Screening Progress in Phase 2 ALTITUDE-AD Trial and Preclinical Research Methods at AD/PD 2025 and AAN Annual Meeting
Acumen Pharmaceuticals, Inc. (ABOS) Q4 2024 Earnings Call Transcript
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025
Acumen Pharmaceuticals CEO Discusses Novel Targeted Therapies for Alzheimer's
Acumen Pharmaceuticals to Present During International Conference on Alzheimer's and Parkinson's Diseases 2025 and American Academy of Neurology Annual Meeting
Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences
Acumen Pharmaceuticals to Participate in the 7th Annual Evercore ISI HealthCONx Conference
Acumen Pharmaceuticals, Inc. (ABOS) Q3 2024 Earnings Call Transcript
Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference
Acumen Pharmaceuticals to Participate in the UBS Global Healthcare Conference
Acumen Pharmaceuticals Presents Innovative Trial Screening Advancements Utilizing pTau217 Assay in Phase 2 Study of Sabirnetug for Early Alzheimer's Disease at the 17th Annual Clinical Trials on Alzheimer's Disease Conference
Acumen Pharmaceuticals to Deliver Late-Breaking Presentation at 17th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference
Acumen Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference
Acumen Pharmaceuticals to Host Virtual R&D Day on Oct. 2, 2024
Acumen Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investor Conference
Acumen Pharmaceuticals, Inc. (ABOS) Q2 2024 Earnings Call Transcript
Acumen Pharmaceuticals to Report Second Quarter Results on August 13, 2024
Acumen Pharmaceuticals: Healthy Cash Runway And Market Potential In Alzheimer's